Portola Pharmaceuticals recently announced that the U.S. Food and Drug Administration (FDA) did not approve its antidote for uncontrolled bleeding linked to blood thinners including Xarelto (rivaroxaban) and Eliquis (apixaban).
The FDA designated Portola’s drug, AndexXa (andexanet alfa), a Breakthrough Therapy and granted it expedited review. But the agency said it needs more information before approval.
Currently, there is no reversal agent for uncontrolled bleeding linked to these drugs. Internal bleeding adverse events linked to Xarelto include fatal brain and stomach bleeds.
Doctors prescribe blood thinners to prevent strokes and blood clots following surgery and for people with atrial fibrillation. For decades, warfarin (Coumadin) was the gold-standard blood thinner. But newer anticoagulants such as Xarelto do not require blood tests or dietary restrictions like warfarin.
“Because AndexXa addresses an urgent unmet medical need, we and the FDA are committed to resolving the outstanding questions and determining appropriate next steps. Portola’s goal is to define the most expedient path to approval so we can meet the needs of these patients who have no alternative,” Bill Lis, chief executive officer of Portola, said in a statement. “We plan to meet with the FDA as soon as possible.”
On Aug. 17, Portola received the FDA‘s complete response letter to its application for approval. The agency requested additional information on the drug’s manufacturing and said it needed to review changes Portola made to its post-marketing commitments.
AndexXa’s Phase III clinical trial data showed it rapidly reversed the anticoagulant effects of Eliquis (apixaban). The company expects to resubmit its application before the end of the year, according to a statement.
Portola’s shares fell by a third.
Lack of an antidote also affects patients who use Xarelto and other Factor Xa blood thinners. As the number of adverse events climb, so do lawsuits. Attorneys for plaintiffs mention lack of an antidote in a number of uncontrolled bleeding claims facing J&J and Bayer.
“The original U.S. label approved when the drug was first marketed in the U.S. did not contain a warning regarding the lack of antidote, but instead only mentioned this important fact in the overdosage section,” one lawsuit said.
So far, more than 7,200 federal lawsuits are pending before U.S. District Judge Eldon E. Fallon in Louisiana. J&J is aware of the growing claims.
“The number of pending product liability lawsuits continues to increase, and the Company continues to receive information with respect to potential costs and the anticipated number of cases,” the company said in its 2015 Annual report.
Fallon scheduled the first bellwether trials for February.
Drugwatch.com writers follow rigorous sourcing guidelines and cite only trustworthy sources of information, including peer-reviewed journals, court records, academic organizations, highly regarded nonprofit organizations, government reports and interviews with qualified experts. Review our editorial policy to learn more about our process for producing accurate, current and balanced content.
Calling this number connects you with one of Drugwatch's trusted legal partners. A law firm representative will review your case for free.
Drugwatch's trusted legal partners support the organization’s mission to keep people safe from dangerous drugs and medical devices. For more information, visit our partners page.(888) 645-1617